LLY Jan 2025 640.000 call
| Previous Close | 42.40 |
| Open | 42.40 |
| Bid | 37.65 |
| Ask | 38.85 |
| Strike | 640.00 |
| Expire Date | 2025-01-17 |
| Day's Range | 42.40 - 42.40 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 479 |
BloombergTraders Gain 1000% in a Day on Timely Point Biopharma Option Bet
(Bloomberg) -- A well-timed options trade in Point Biopharma Global Inc. stands to hand some investors upwards of $500,000 after Eli Lilly & Co.’s agreement to acquire the company sent its stock surging.Most Read from BloombergWhy a US Recession Is Still Likely — and Coming SoonKey Taiwan Tech Firms Helping Huawei With China Chip PlantsAirbnb Is Fundamentally Broken, Its CEO Says. He Plans to Fix It.US Stocks, Bonds Pummeled by Too Hot Jobs Data: Markets WrapJPMorgan’s Dimon Predicts 3.5-Day Wor
ZacksWhy Investors Need to Take Advantage of These 2 Medical Stocks Now
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
ZacksLilly's (LLY) Eczema Candidate Lebrikizumab Faces FDA Rejection
Lilly (LLY) gets a CRL for the eczema candidate, lebrikizumab, based on inspection findings at a third-party manufacturer.
